Nuclear Medicine Radioisotopes Market Outlook 2025–2029: Regional Growth and Sizing Insights

 Get 20% Off Market Intelligence Reports With Code ONLINE20 — Track Global Tariffs, Economic Shifts, and Sector Transformations

 

 What Are the Long-Term Growth Opportunities and Market Size Outlook for the Nuclear Medicine Radioisotopes Market?
 The nuclear medicine radioisotopes market size has grown strongly in recent years. It will grow from $8.21 billion in 2024 to $8.85 billion in 2025 at a compound annual growth rate (CAGR) of 7.9%. The growth in the historic period can be attributed to discovery of radioactivity, emergence of nuclear medicine, therapeutic applications, clinical research, and patient demand.
 
 The nuclear medicine radioisotopes market size is expected to see strong growth in the next few years. It will grow to $11.96 billion in 2029 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to increasing healthcare spending, expansion of healthcare infrastructure, growing awareness of environmental sustainability, education campaigns and awareness programs and growth in medical tourism. Major trends in the forecast period include development of new radioisotopes, production and supply chain innovations, microfluidics and lab-on-a-chip technology, artificial intelligence in radiopharmaceutical development and nanotechnology.
 
 Claim your free report sample now:
 https://www.thebusinessresearchcompany.com/sample.aspx?id=16132&type=smp
 
 What Are the Key Drivers of the Nuclear Medicine Radioisotopes Market?
 The rising cases of cardiovascular diseases are expected to propel the growth of the nuclear medicine radioisotope market going forward. Cardiovascular diseases refer to a group of diseases that affect the heart and blood vessels. The rising cases of cardiovascular diseases are due to sedentary lifestyles, poor dietary habits, increasing rates of obesity, and aging populations. The nuclear medicine radioisotopes are invaluable in diagnosing, evaluating, and managing cardiovascular diseases with detailed insights into cardiac function, perfusion, and tissue viability, which are essential for accurate diagnosis and effective treatment planning. For instance, in September 2024, according to the data published by the British Heart Foundation, a UK-based cardiovascular research charity, in the UK, approximately 7.6 million people are affected by heart and circulatory diseases, with around 4 million males and 3.6 million females living with these conditions. These diseases are responsible for about 27% of all deaths in the UK, translating to over 170,000 deaths annually, or roughly 480 deaths each day, equating to one death every three minutes. Therefore, the rising cases of cardiovascular diseases are driving the growth of the nuclear medicine radioisotope market.
 
 How Is the Nuclear Medicine Radioisotopes Market Divided by Type and Application?
 The nuclear medicine radioisotopes market covered in this report is segmented — 
 
 1) By Type: Technetium-99m (Tc-99m), Thallium-201 (Tl-201), Iodine (I-123), Fluorine-18, Rubidium-82 (Rb-82), Iodine-131 (I-131), Lutetium-177 (Lu-177), Radium-223 (Ra-223) And Alpharadin, Other Types
 2) By Application: Oncology, Cardiology, Thyroid, Neurology, Other Applications
 3) By End-User: Hospitals, Diagnostic Centers, Specialty Clinics, Education And Research Institutes, Other End-Users
 
 Subsegments:
 1) By Technetium-99m (Tc-99m): Sodium Pertechnetate Tc-99m, Tc-99m MDP (Methylene Diphosphonate), Tc-99m HMPAO (Hexamethylpropyleneamine oxime) 
 2) By Thallium-201 (Tl-201): Thallous Chloride Tl-201, Thallium-201 for Cardiac Imaging 
 3) By Iodine-123 (I-123): Iodine-123 Sodium Iodide, Iodine-123 Ioflupane (DaTscan) 
 4) By Fluorine-18: FDG (Fluorodeoxyglucose) F-18, Fluoride-18 For Bone Imaging 
 5) By Rubidium-82 (Rb-82): Rb-82 For PET (Positron Emission Tomography) Imaging, Rb-82 For Cardiac Imaging 
 6) By Iodine-131 (I-131): I-131 Sodium Iodide, I-131 For Thyroid Cancer Treatment, I-131 For Hyperthyroidism Treatment 
 7) By Lutetium-177 (Lu-177): Lu-177-DOTATATE, Lu-177 For Prostate Cancer Treatment 
 8) By Radium-223 (Ra-223): Ra-223 Dichloride (Xofigo) 
 9) By Alpharadin (Radium-223 Alpha Emitters): Alpharadin For Bone Metastasis Treatment 
 10) By Other Types: Ac-225 For Targeted Alpha Therapy (TAT), Ac-225 For Cancer Treatment, Gallium-68 (Ga-68), Copper-64 (Cu-64), Yttrium-90 (Y-90)
 
 Which Emerging Trends Are Driving the Nuclear Medicine Radioisotopes Market?
 Major companies operating in the nuclear medicine radioisotopes market are focusing on developing innovative products, such as the compact low-energy cyclotron, to improve the production and availability of radioisotopes, ensuring more efficient and accessible diagnostic and therapeutic options. A compact, low-energy cyclone is a small particle accelerator used to create radioisotopes for medical imaging and treatments in nuclear medicine. For instance, in January 2022, IBA, a Belgium-based provider of radiopharmaceutical production solutions, launched Cyclone Key, a new accelerator providing increased access to diagnostic solutions and enabling in-house production of radiopharmaceuticals. This innovative solution offers unique features such as a compact and efficient design, fully automated operation, multiple isotope production capabilities, ease of installation and operation, water cooling, self-shielding, and high performance, making it versatile and reliable.
 
 What Are the Top Companies to Watch in the Nuclear Medicine Radioisotopes Market?
 Major companies operating in the nuclear medicine radioisotopes market are Cardinal Health Inc., Bayer AG, Siemens Healthineers AG, GE HealthCare Technologies, BWX Technologies Inc., Mallinckrodt Pharmaceuticals, Bracco Imaging S.p.A., Lantheus Holdings Inc., Curium Pharma, Australian Nuclear Science and Technology Organisation (ANSTO) Health, Eckert & Ziegler Strahlen, NorthStar Medical Radioisotopes, NTP Radioisotopes, Shine Medical Technologies Inc., Jubilant DraxImage Inc., Isotopia Molecular Imaging Ltd., Eczacibasi-Monrol Nuclear Products, International Isotopes Inc., Polatom Sp. z o.o., Radiomedix Inc., Positron Corporation
 
 Get the full nuclear medicine radioisotopes market report here:
 https://www.thebusinessresearchcompany.com/report/nuclear-medicine-radioisotopes-global-market-report
 
 How Does Nuclear Medicine Radioisotopes Market Growth Vary Across Major Regions?
 North America was the largest region in the nuclear medicine radioisotopes market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the nuclear medicine radioisotopes market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
 
 Contact Us:
 
 The Business Research Company 
 
 https://thebusinessresearchcompany.com/ 
 
 Americas +1 310–496–7795
 Asia +44 7882 955267 & +91 8897263534
 Europe +44 7882 955267 
 
 Email: info@tbrc.info 
 
 
 Follow Us On:
 
 LinkedIn: https://in.linkedin.com/company/the-business-research-company